Next Science Ltd (nxs) Logo

Next Science Ltd (NXS)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

NXS Chart

Snapshot

NXS's Principal Activity is the research, development and commercialisation of technologies which solve issues in human health caused by biofilms.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -1.06%
vs ASX 200 (1yr) -18.91%

Size

Market Capitalisation
ASX Rank 675 of 2,316
Sector Rank 51 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies HLA / IPD / EOF
EPS -$0.057
DPS $0.00
NTA per share $0.09

Broker Consensus

NXS is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Next Science Limited (NXS) is a medical technology with research, development and commercialisation of technologies which solve issues in human health caused by biofilms. The company is headquartered in Sydney, Australia and has a research and development centre in Florida, USA.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Chatswood NSW 2067
Website www.nextscience.com
Registry Link Market Services
Auditor KPMG
Date Listed 18 Apr 2019

Upcoming Calendar (Forecasted)

Date Event
21/02/2022 Report (Prelim)
22/02/2022 Report (Prelim)
31/03/2022 Report (Annual)
12/04/2022 Report (Quarterly)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Mark Raymond Compton Non-Executive Director,Non-Executive Chairman Oct 2018 Director Bio icon

Mr Mark Raymond Compton

Non-Executive Director,Non-Executive Chairman

Mr Compton is Lord Prior of the International Order of St John and Chairman of the Board of Trustees of St John International. He is also Chairman of St Luke's Care Limited and Chairman of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held range of CEO and managing director roles, including at St Luke's Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012). He is a member of People, Culture Committee.

Mrs Aileen Stockburger Non-Executive Director Oct 2018 Director Bio icon

Mrs Aileen Stockburger

Non-Executive Director

Mrs Stockburger was the Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson's efforts to acquire Synthes. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also part of range of other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He is a Non-Executive Director of Microbot Medical Inc. She is a member of Risk Committee.

Ms Gillian Maria Nairn Company Secretary Jun 2018
Mr Bruce Alan Hancox Non-Executive Director Oct 2017 Director Bio icon

Mr Bruce Alan Hancox

Non-Executive Director

Mr Hancox has over 35 years of corporate experience across commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and Chairman and served on the board of a number of their subsidiaries in New Zealand, Australia and the US. Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market. He is a Director of Walker Group Holdings Pty Limited. He is Chair of the Risk Committee.

Mr Daniel (Dan) Spira Non-Executive Director Oct 2017 Director Bio icon

Mr Daniel (Dan) Spira

Non-Executive Director

Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM North America and was also Managing Director, Pacific region. Prior to that, Daniel spent over 15 years at Johnson & Johnson Inc in range of roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions. He is a Chair of People, Culture Committee.

Ms Judith Mitchell Managing Director Oct 2017 Director Bio icon

Ms Judith Mitchell

Managing Director

Ms Mitchell served as President of DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson, before which Judith was President of Asia Pacific for Synthes GmbH. Judith commenced her medical technology career at GE Medical Systems, where over 14 years, she held positions in sales, marketing and management. She also held a range of positions at Cochlear Limited in Product Development, Global Marketing and Education.

Dustin Haines Chief Commercial Officer N/A
Jacqueline Butler Chief Financial Officer N/A
Jon Swanson Chief Operating Officer N/A
Matthew Myntti Chief Technology Officer N/A

Director Transactions

NXS directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
28/04/21 Daniel (Dan) Spira Sell +3,487 $1.71 ($5,962) As advised by the company
26/04/21 Daniel (Dan) Spira Sell +362,342 $1.57 ($568,876) As advised by the company
13/04/21 Daniel (Dan) Spira Exercise 1,040,000 $0.55 $572,000 Exercise of options
13/04/21 Daniel (Dan) Spira Buy +1,040,000 $0.55 $572,000 Exercise of options
24/11/20 Bruce Hancox Buy +130,000 $1.149 $149,344 On-market trade
24/11/20 Judith Mitchell Buy +24,362 $1.14 $27,772 On-market trade
24/11/20 Judith Mitchell Buy +43,000 $1.14 $49,020 On-market trade
29/10/20 Judith Mitchell Buy +22,438 $1.155 $25,907 On-market trade
29/10/20 Judith Mitchell Buy +178,200 $1.155 $205,755 On-market trade
28/10/20 Bruce Hancox Buy +30,000 $1.16 $34,800 On-market trade
19/10/20 George Savvides Buy +24,876 $1.18 $29,353 Participation in share purchase plan
19/10/20 Mark Compton Buy +12,438 $1.18 $14,676 Participation in share purchase plan
19/10/20 Judith Mitchell Buy +12,438 $1.18 $14,676 Participation in share purchase plan
02/10/20 Bruce Hancox Buy +154,330 $1.24 $191,369 On-market trade
24/09/20 Bruce Hancox Buy +70,000 $1.24 $86,800 On-market trade
24/09/20 Bruce Hancox Buy +145,670 $1.206 $175,707 On-market trade
06/05/20 Aileen Stockburger Issued 11,283 $1.99 $22,453 Director remuneration
06/05/20 Daniel (Dan) Spira Issued 12,537 $1.99 $24,948 Director remuneration
19/12/19 Aileen Stockburger Issued 7,977 $2.82 $22,495 Director remuneration
19/12/19 Dan Spira Issued 8,865 $2.82 $24,999 Director remuneration
25/09/19 Dan Spira Issued 27,864 $1.674 $46,644 Director remuneration
25/09/19 Aileen Stockburger Issued 25,577 $1.661 $42,475 Director remuneration

Director Interests

The current holdings of NXS directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Daniel (Dan) Spira 28/04/2021 723,437 N/A 260,000 N/A
Judith Mitchell 31/12/2020 4,778,800 221,200 2,340,000 N/A
Aileen Stockburger 31/12/2020 44,837 N/A 520,000 N/A
Bruce Hancox 31/12/2020 460,000 70,000 520,000 N/A
Mark Compton 31/12/2020 N/A 137,438 520,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Feb 19, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Auckland Trust Company Ltd ATF Secord Pacific Master Superannuation Fund 56,019,938 28.85%
Walker Group Holdings Pty Limited 21,719,667 11.18%
Matthew Myntti 20,657,000 10.64%
HSBC Custody Nominees (Australia) Limited A/C 2 6,299,588 3.24%
Merrill Lynch (Australia) Nominees Pty Limited 5,130,056 2.64%
Judith Mitchell 4,744,438 2.44%
HSBC Custody Nominees (Australia) Limited 3,534,393 1.82%
UBS Nominees Pty Ltd 3,464,130 1.78%
Mr Charles Robert Dirck Wittenoom 2,825,000 1.45%
National Nominees Limited 2,443,875 1.26%
Citicorp Nominees Ply Limited 1,637,135 0.84%
Scone Investments Pty Ltd 1,159,452 0.60%
G & N Lord Superannuation Pty Ltd <GNR Superannuation Fund A/C> 965,000 0.50%
Mr Byron James Darroch 962,500 0.50%
Ka-tet Pty Ltd <The Rosenrot Trust> 890,500 0.46%
Donald Ayers 672,394 0.35%
Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C> 625,000 0.32%
Authentics Australia Pty Ltd <Authentics Australia A/C> 512,438 0.26%
Tsunami Ventures Pty Ltd <Drizzle Family A/C> 500,938 0.26%
Honne Investments Pty Limited 500,000 0.26%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 98 1,082 874 1,988 1,510 5,552

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Langley Alexander Walker 19/02/2021 76,072,938 39.53
Matthew Myntti 03/09/2021 14,068,000 7.11

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
03-09-21 Matthew Myntti 6,589,000 11.5 7.11

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $1.25 30 June
2019 $4.11 28 June
2014 $0.013 30 June
Page Icon
NXS Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.